The state of the IP union

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

The state of the IP union

Alice was the dominant topic in the AIPLA session "Addressing the Hot Topics of Today for Tomorrow's Business"

The first question that moderator Timothy Meigs of Beckton Dickinson asked the State of the IP Union Panel yesterday was: what keeps them and their clients up at night? The panel's subtitle was "Addressing the Hot Topics of Today for Tomorrow's Business," but the answer to this question was hardly a hot and fresh one: it's still Alice.

Philip Petti of USG Corporation commented: "It's sort of like we're sitting in the middle of the bus, and there's a crazy person at the wheel." Petti says he and his company feel the "reverberations" of the uncertainty brought on by Alice. From the statistics he's examined, "if our patents are tested, about 70% of them are going to fail," he said. "How do I advise my business people when I tell them we're going to put so much money into patenting that you can't even count on?"

As Microsoft's Micky Minhas sees it, Alice may be dissuading IP owners from other countries from patenting their products here, placing the US at a disadvantage. As China considers accepting patents for business methods, the US is heading "in the opposite direction," he said.

Pfizer's Adrian Looney praised Hatch-Waxman and the BPCIA for clearing the way for generics. But he also questioned whether, if the Alice decision had been handed down before the boom of generics, those pharmaceuticals that have saved many lives would even exist today. It was suggested that it is not just innovation in the biopharma space that Alice stands to inhibit. Qualcomm's Laurie Self said that funding for startups "depends on the VC community believing that you have a predictable right, an enforceable right." She added: "I really do worry that, through this constant diminishment of patent rights, you're making long-term research too risky an investment for startups."

Looney also pointed to the specificity of Hatch-Waxman litigation to one industry as a potential model for reform to 101 issues, which have been treated very inconsistently by the courts. Frustrating though the denial of cert for a number of recent 101 cases is, the panel conceded the Supreme Court has heard a number of IP cases and may still want to see the lower courts shake it out.

more from across site and SHARED ros bottom lb

More from across our site

Yossi Sivan explains how Israeli judgment is a pro-brand owner departure from the norm and why it sends a strong message that corporate structures are not always a shield
Halim Shehadeh, group CEO of IP firm CWB, says that in the rush to discuss what AI can do, IP firms are overlooking the more important question of whether they are ready
Caitlin Heard, who formally joined the firm from CMS last month, says she is excited by the ‘energy’ of the London office
Ranjna Mehta-Dutt, who moved to Chadha & Chadha after 25 years at Remfry & Sagar, says the firm plans to expand its life sciences practice through targeted recruitment and dedicated teams for bigger clients
The initial contempt of court claim targeted Stobbs and the firm’s client for allegedly interfering with the administration of justice
Acquisition of platform developed by Boehmert & Boehmert lawyer set to create a combined platform for patent drafting and prosecution in Europe
Partner Rob Jacob unveils plans to offer a beginning-to-end trademark service, how to make prosecution profitable, and why IP ‘buy-in’ from the CEO stands the firm in good stead
Attorneys at Di Blasi, Parente & Associados share how the protection of trade secrets strengthens innovation by bringing together legal practice, regulatory developments, and established international references
Jin Ooi, who joins as a partner today, said he is excited to offer a ‘rounded’ IP service as the firm deepens its litigation expertise in the UK and Europe
As generics celebrate, practitioners believe innovator companies should brace for an ‘uphill battle’ when trying to prove induced infringement
Gift this article